GeneDx Corp.

NASDAQ: WGS · Real-Time Price · USD
124.56
1.68 (1.37%)
At close: Aug 15, 2025, 12:40 PM

GeneDx Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
305.45M 202.57M 234.69M 212.19M
Cost of Revenue
111.05M 141.94M 261.44M 228.8M
Gross Profit
194.4M 60.62M -26.75M -16.6M
Operating Income
-23.21M -163.66M -667.65M -446.15M
Interest Income
n/a 1.11M 2.54M 79K
Pretax Income
-52.63M -176.69M -598.03M -245.39M
Net Income
-52.29M -175.77M -548.98M -245.39M
Selling & General & Admin
168.48M 194.71M 338.24M 318.73M
Research & Development
45.72M 58.27M 86.2M 105.16M
Other Expenses
3.41M -28.69M 6.31M 5.66M
Operating Expenses
217.61M 224.28M 430.76M 429.55M
Interest Expense
3.03M n/a 3.21M 2.83M
Selling & Marketing Expenses
67.37M 60.96M 134.91M 112.74M
Cost & Expenses
328.66M 366.23M 692.2M 658.34M
Income Tax Expense
-343K -926K -49.05M n/a
Shares Outstanding (Basic)
26.89M 24.31M 10.24M 3.28M
Shares Outstanding (Diluted)
26.89M 24.31M 10.24M 3.28M
EPS (Basic)
-1.94 -7.23 -53.63 -74.93
EPS (Diluted)
-1.94 -7.23 -53.63 -74.93
EBITDA
-27.64M -136.46M -398.2M -219.19M
EBIT
-49.6M -170.19M -457.51M -242.56M
Depreciation & Amortization
21.95M 33.73M 63.03M 23.36M